PHARMACONTROL SODIUM ACETYLSALICYLATE CLASSIFICATION AS "SUBSET OF ASPIRIN"
PHARMACONTROL SODIUM ACETYLSALICYLATE CLASSIFICATION AS "SUBSET OF ASPIRIN" should be established by FDA, qualifying the drug for Category I OTC status, the company said in a recent letter to the agency. In the letter, PharmaControl's outside attorney Robert Pinco (D.C. law firm Perito, Duerk and Pinco) requested an advisory opinion from the agency that "sodium acetylsalicylate is generally recognized as safe and effective for OTC use as a subset of aspirin when labeled as an analgesic active ingredient for oral administration." Alternatively, the company asserted, "if aspirin and its sodium salt are to be differentiated by the agency, the opinion should verify the implicit and/or explicit recommendations of two expert advisory panels that sodium acetylsalicylate is itself generally recognized as safe and effective." PharmaControl stated that both the FDA OTC Internal Analgesic, Antipyretic and Antirheumatic Panel and the Miscellaneous Internal Panel treated aspirin (acetylsalicylic acid) and sodium aspirn (sodium acetylsalicylate) as "regulatory synonyms." The company noted that both panels "placed aspirin in Category I, reaching the determination that this ingredient was generally recognized as safe and effective for OTC use as an internal analgesic." PharmaControl said "although sodium acetylsalicylate is not listed by name as a Category I active ingredient in either of the two panel reports, it is clear from panel minutes that both panels in their deliberations on aspirin specifically considered studies on sodium acetylsalicylate." PharmaControl has developed an oral soluble sodium aspirin produc which it has optioned to McNeil. The company has also developed an injectable form of sodium acetylsalicylate. PharmaControl President and CEO Max Tesler, MD, indicated firm is in the last stages "of negotiations with a major pharmaceutical company to give them the marketing rights for the [injectable] product."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth